Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer
Background Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. Methods We compared pat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2016
|
| _version_ | 1826276433534648320 |
|---|---|
| author | Donovan, J Hamdy, F Lane, J Mason, M Metcalfe, C Walsh, E Blazeby, J Peters, T Holding, P Bonnington, S Lennon, T Bradshaw, L Cooper, D Herbert, P Howson, J Jones, A Lyons, N Salter, E Thompson, P Tidball, S Blaikie, J Gray, C Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Davis, M Turner, E Martin, R Neal, D ProtecT Study Group |
| author_facet | Donovan, J Hamdy, F Lane, J Mason, M Metcalfe, C Walsh, E Blazeby, J Peters, T Holding, P Bonnington, S Lennon, T Bradshaw, L Cooper, D Herbert, P Howson, J Jones, A Lyons, N Salter, E Thompson, P Tidball, S Blaikie, J Gray, C Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Davis, M Turner, E Martin, R Neal, D ProtecT Study Group |
| author_sort | Donovan, J |
| collection | OXFORD |
| description | Background Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. Methods We compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually thereafter. Patients completed validated measures that assessed urinary, bowel, and sexual function and specific effects on quality of life, anxiety and depression, and general health. Cancer-related quality of life was assessed at 5 years. Complete 6-year data were analyzed according to the intention-to-treat principle. Results The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes remained worse in the prostatectomy group than in the other groups throughout the trial. The negative effect of radiotherapy on sexual function was greatest at 6 months, but sexual function then recovered somewhat and was stable thereafter; radiotherapy had little effect on urinary continence. Sexual and urinary function declined gradually in the active-monitoring group. Bowel function was worse in the radiotherapy group at 6 months than in the other groups but then recovered somewhat, except for the increasing frequency of bloody stools; bowel function was unchanged in the other groups. Urinary voiding and nocturia were worse in the radiotherapy group at 6 months but then mostly recovered and were similar to the other groups after 12 months. Effects on quality of life mirrored the reported changes in function. No significant differences were observed among the groups in measures of anxiety, depression, or general health-related or cancer-related quality of life. Conclusions In this analysis of patient-reported outcomes after treatment for localized prostate cancer, patterns of severity, recovery, and decline in urinary, bowel, and sexual function and associated quality of life differed among the three groups. (Funded by the U.K. National Institute for Health Research Health Technology Assessment Program; ProtecT Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .). |
| first_indexed | 2024-03-06T23:13:53Z |
| format | Journal article |
| id | oxford-uuid:667244bf-1f62-42cb-a4a8-3332b6bf6f25 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:13:53Z |
| publishDate | 2016 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:667244bf-1f62-42cb-a4a8-3332b6bf6f252022-03-26T18:32:00ZPatient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:667244bf-1f62-42cb-a4a8-3332b6bf6f25EnglishSymplectic Elements at OxfordMassachusetts Medical Society2016Donovan, JHamdy, FLane, JMason, MMetcalfe, CWalsh, EBlazeby, JPeters, THolding, PBonnington, SLennon, TBradshaw, LCooper, DHerbert, PHowson, JJones, ALyons, NSalter, EThompson, PTidball, SBlaikie, JGray, CBollina, PCatto, JDoble, ADoherty, AGillatt, DKockelbergh, RKynaston, HPaul, APowell, PPrescott, SRosario, DRowe, EDavis, MTurner, EMartin, RNeal, DProtecT Study GroupBackground Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. Methods We compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually thereafter. Patients completed validated measures that assessed urinary, bowel, and sexual function and specific effects on quality of life, anxiety and depression, and general health. Cancer-related quality of life was assessed at 5 years. Complete 6-year data were analyzed according to the intention-to-treat principle. Results The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes remained worse in the prostatectomy group than in the other groups throughout the trial. The negative effect of radiotherapy on sexual function was greatest at 6 months, but sexual function then recovered somewhat and was stable thereafter; radiotherapy had little effect on urinary continence. Sexual and urinary function declined gradually in the active-monitoring group. Bowel function was worse in the radiotherapy group at 6 months than in the other groups but then recovered somewhat, except for the increasing frequency of bloody stools; bowel function was unchanged in the other groups. Urinary voiding and nocturia were worse in the radiotherapy group at 6 months but then mostly recovered and were similar to the other groups after 12 months. Effects on quality of life mirrored the reported changes in function. No significant differences were observed among the groups in measures of anxiety, depression, or general health-related or cancer-related quality of life. Conclusions In this analysis of patient-reported outcomes after treatment for localized prostate cancer, patterns of severity, recovery, and decline in urinary, bowel, and sexual function and associated quality of life differed among the three groups. (Funded by the U.K. National Institute for Health Research Health Technology Assessment Program; ProtecT Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .). |
| spellingShingle | Donovan, J Hamdy, F Lane, J Mason, M Metcalfe, C Walsh, E Blazeby, J Peters, T Holding, P Bonnington, S Lennon, T Bradshaw, L Cooper, D Herbert, P Howson, J Jones, A Lyons, N Salter, E Thompson, P Tidball, S Blaikie, J Gray, C Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Paul, A Powell, P Prescott, S Rosario, D Rowe, E Davis, M Turner, E Martin, R Neal, D ProtecT Study Group Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title | Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title_full | Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title_fullStr | Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title_full_unstemmed | Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title_short | Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer |
| title_sort | patient reported outcomes after monitoring surgery or radiotherapy for prostate cancer |
| work_keys_str_mv | AT donovanj patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT hamdyf patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT lanej patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT masonm patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT metcalfec patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT walshe patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT blazebyj patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT peterst patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT holdingp patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT bonningtons patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT lennont patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT bradshawl patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT cooperd patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT herbertp patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT howsonj patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT jonesa patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT lyonsn patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT saltere patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT thompsonp patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT tidballs patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT blaikiej patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT grayc patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT bollinap patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT cattoj patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT doblea patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT dohertya patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT gillattd patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT kockelberghr patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT kynastonh patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT paula patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT powellp patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT prescotts patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT rosariod patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT rowee patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT davism patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT turnere patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT martinr patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT neald patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer AT protectstudygroup patientreportedoutcomesaftermonitoringsurgeryorradiotherapyforprostatecancer |